Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Contract Services
- Pharmaceutical Business Review White Papers | Suppliers | Companies
Register with PBR
Return to: PBR Home | Contract Research & Services | Contract Services
Ignyta, Nerviano sign license deal for two first-in-class kinase inhibitors
Ignyta (RXDX), an oncology precision medicine biotechnology company, and Nerviano Medical Sciences, an oncology discovery organization, have signed a license agreement that grants Ignyta exclusive global development and commercialization rights to two new drug development programs, which Ignyta will refer to as RXDX-103 and RXDX-104.
Contract Research & Services > Contract Services > News
Infinity Pharmaceuticals amends PI3K-delta, gamma agreement with Millennium
Infinity Pharmaceuticals has purchased an option to buy out all future potential royalty payments due to Millennium: The Takeda Oncology Company for sales in oncology of IPI-145, Infinity’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
Contract Research & Services > Contract Services > News
Amarantus acquires option to license Alzheimer's therapeutic IP of Dr. Thomas Arendt
Amarantus Bioscience Holdings (AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3rd Alzheimer's focused Coalition for Concussion Treatment Summit.
Contract Research & Services > Contract Services > News
ZIOPHARM, Solasia Pharma ink license deal for darinaparsin
By PBR Staff Writer
US-based biopharmaceutical firm ZIOPHARM Oncology and Solasia Pharma, Japanese developer of oncology pharmaceuticals, have announced amendment and restatement of their license and collaboration agreement for darinaparsin (Zinapar or ZIO-101) and related organoarsenic molecules.
Contract Research & Services > Contract Services > News
Angelini to commercialize Durata's Dalbavancin in certain European Territories, Russia and Turkey
By PBR Staff Writer
Durata Therapeutics International, the Dutch subsidiary of US-based Durata Therapeutics, has entered into a license and supply agreement with Angelini, an international group leader in the pharmaceutical and mass-market sectors, to commercialize dalbavancin in 36 countries.
Contract Research & Services > Contract Services > News
Anika Therapeutics, Medline enter commercialization deal for Hyalomatrix
By PBR Staff Writer
US-based Anika Therapeutics has entered into a new agreement with Medline Industries to commercialize the company's advanced wound care product 'Hyalomatrix', in the US on an exclusive basis through 2019.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests

Report Store

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250

Sign up for the latest PBR news and features as well as other industry newsletters.